NewAmsterdam Pharma N.V. (NAMSW)
11.96
-0.55 (-4.40%)
At close: Mar 25, 2025, 2:54 PM
12.95
8.31%
After-hours: Mar 25, 2025, 04:13 PM EDT
-4.40% (1D)
| Bid | 11.59 |
| Market Cap | 2.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 15.75 |
| Volume | 111 |
| Avg. Volume (20D) | 2,411 |
| Open | 11.96 |
| Previous Close | 12.51 |
| Day's Range | 11.96 - 11.96 |
| 52-Week Range | 5.52 - 16.75 |
| Beta | -0.04 |
About NAMSW
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol NAMSW